Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
71 participants
INTERVENTIONAL
2024-03-15
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227690
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
NCT01851603
In-Patient Study In Schizophrenic Patients
NCT00197093
A Trial to Assess the Antipsychotic Efficacy of ITI-007
NCT02282761
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ANAVEX3-71 30 mg TID (Part A)
The first active treatment arm of the study during Part A (multiple ascending doses).
ANAVEX3-71 oral capsules
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
ANAVEX3-71 60 mg TID (Part A)
The second active treatment arm of the study during Part A (multiple ascending doses).
ANAVEX3-71 oral capsules
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
ANAVEX3-71 Placebo TID (Part A)
The placebo arm of Part A (multiple ascending doses).
Placebo oral capsules
The placebo comparator for the study.
ANAVEX3-71 TBD mg TID (Part B)
The active arm of Part B of the study. The dose will be determined based on data obtained in Part A.
ANAVEX3-71 oral capsules
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
ANAVEX3-71 Placebo TID (Part B)
The placebo arm of Part B of the study.
Placebo oral capsules
The placebo comparator for the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANAVEX3-71 oral capsules
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
Placebo oral capsules
The placebo comparator for the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has a primary diagnosis of schizophrenia, for ≥ 1 year
3. Stable schizophrenia psychiatric symptoms for at least 6 weeks prior to screening.
4. Schizophrenia clinical symptom severity defined by meeting ALL of the following per the Positive and Negative Syndrome Scale (PANSS) item scores at screening:
1. Delusions (P1) ≤ 4
2. Hallucinatory behavior (P3) ≤ 4
3. Unusual thought content (G9) ≤ 4
4. Hostility (P7) ≤ 4
5. Patient has a PANSS total score ≤ 80 at screening and baseline visits and no worsening in PANSS total score between screening and baseline, of more than 20%.
6. Has a Brief Assessment of Cognition (BACS) T-score \< 50 at the screening visit.
7. On a stable regimen of at least one and up to a maximum of two second-generation ("atypical") antipsychotic medications for at least 6 weeks prior to screening and agree to stay on this regimen for their entire study participation, with the following exceptions:
1. Clozapine use is not permitted
2. Quetiapine for sleep at doses less than 300 mg are permitted.
3. Day time (including morning) quetiapine use as the background antipsychotic is not permitted.
8. Able to understand the requirements of the study and able and willing to provide written informed consent and to abide by the study procedures, in the judgment of the Investigator, including able and willing to remain in an in-patient setting during the study.
9. If of childbearing potential, using adequate contraceptive methods for the duration of the study.
10. Body mass index of 18.5 to 40.0 kg/m2 (inclusive) and total body weight \> 50 kg (110 lbs.) for males and \> 40 kg (88 lbs.) for females.
11. Has a negative urine screen for drugs of abuse and negative alcohol breath test at screening and check-in.
12. Patient resides in a stable living situation and is anticipated to return to that same stable living situation.
Exclusion Criteria
2. History or presence of a clinically significant, poorly treated, or unstable conditions that would jeopardize the safety of the patient or the validity of the study results.
3. Clinically significant abnormal findings on the physical examination, medical history, ECG, or clinical laboratory results at screening.
4. Calgary Depression Scale for schizophrenia (CDSS) score ≥6 at the screening or baseline visits.
5. Simpson Angus Scale (SAS) total score ≥5 at the screening and baseline visits at the screening or baseline visits.
6. Abnormal Involuntary Movement (AIMS) score of 2 for two or more movements or a score of 3 or 4 for any single movement on this scale at the screening or baseline visits.
7. Any primary the DSM-5-TR (American Psychiatric Association 2022) disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening).
8. Pregnant, lactating, or less than 3 months postpartum. Sperm donation is not allowed for 90 days after the final dose of study drug.
9. Risk for suicidal behavior during the study.
10. Inability to detect a 1000 Hz tone at 40 dB in both ears at screening.
11. Has psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
COGNISION
UNKNOWN
Cognitive Research Corporation
INDUSTRY
Hassman Research Institute
UNKNOWN
Anavex Life Sciences Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kathy Skoff
Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CenExel Hassman Research Institute
Marlton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANAVEX3-71-SZ-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.